Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Acquires 6,146 Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 6,146 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were bought at an average cost of $24.89 per share, with a total value of $152,973.94. Following the transaction, the insider directly owned 6,383,114 shares in the company, valued at $158,875,707.46. This trade represents a 0.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 61,523 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.98 per share, with a total value of $1,536,844.54.
• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.94 per share, with a total value of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock. The shares were bought at an average cost of $24.97 per share, with a total value of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.90 per share, with a total value of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.46 per share, with a total value of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Performance

NASDAQ COAG opened at $26.45 on Thursday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Analysts Set New Price Targets

COAG has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target on the stock. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Wedbush started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hemab Therapeutics has a consensus rating of “Buy” and a consensus target price of $41.40.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.